Our mission is to cure diseases via targets and MoAs that cannot be reached with traditional approaches. Using our unique platform, we optimize peptides/proteins of natural origin using directed evolution to create cutting-edge CGT products or peptide-based pharmaceuticals. VRGT’s management and staff members were selected based on their international research experience and outstanding pharma industry achievements. Our people have outstanding professional expertise in preclinical/clinical R&D and scientific project management, pharmacology, business development and medical marketing. For years, they have worked in the most prestigious academic institutes, such as Fred Hutchinson Cancer Research Center, Karolinska Institute, Harvard University, Weizmann Institute of Science and several leading pharma companies.
Location: Hungary, Central Hungary, Budapest
Employees: 11-50
Total raised: $5.47M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.08.2023 | Series A | $5.47M | Sz�chenyi ... |
Mentions in press and media 5
| Date | Title | Description |
| 17.04.2024 | VRG Therapeutics Advances VRG-145, a Synergistic Oral Combination for Migraine Prophylaxis, to Final Preclinical Stage | VRG Therapeutics Advances VRG-145, a Novel Synergistic Oral Combination for Migraine Prophylaxis, to Final Preclinical Stage BUDAPEST, HUNGARY, April 17, 2024 /EINPresswire.com/ -- VRG Therapeutics (VRG Tx), a leading biotechnology research... |
| 16.01.2024 | VRG Therapeutics announces successful in vivo efficacy results of their CAR-T project targeting glioblastoma | BUDAPEST, HUNGARY, January 16, 2024 /EINPresswire.com/ -- VRG Therapeutics Plc. announces successful in vivo efficacy results of their CAR-T project with patented chlorotoxin analogue targeting glioblastoma, encouraging further development.... |
| 14.08.2023 | VRG Therapeutics has secured €5 Million in Series A Funding | BUDAPEST, HUNGARY, August 14, 2023/EINPresswire.com/ -- VRG Therapeutics (VRG Tx), a pioneering biotechnology research and development company specializing in miniprotein-based pharmaceuticals and cellular & gene therapy (CGT) products,... |
| 26.05.2023 | VRG Therapeutics demonstrates in vivo efficacy with a selective Kv1.3 inhibitor developed for autoimmune diseases | BUDAPEST, HUNGARY, May 26, 2023/EINPresswire.com/ -- VRG Therapeutics, a biotechnology R&D company focused on peptide-based pharmaceuticals and cellular & gene therapy (CGT) products has announced that their exceptionally selective ... |
| - | VRG Therapeutics | “A REGIONAL LEADER IN PRECLINICAL R&D, based on a world-class small protein tech platform and operated by exceptional researchers and industry professionals.” |